These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 6791559)

  • 1. Clinical pharmacology of the antimicrobial agents for infections in the ear, nose and throat.
    Neu HC
    Ann Otol Rhinol Laryngol Suppl; 1981; 90(3 Pt 3):2-7. PubMed ID: 6791559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory diseases of the sinuses: bacteriology and antibiotics.
    Fairbanks DN
    Otolaryngol Clin North Am; 1993 Aug; 26(4):549-59. PubMed ID: 8414527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of antibiotics in otorhinolaryngologic practice].
    Stefan-Mikić S; Sabo A; Jovancević L; Jovićević J; Vasović M; Jakovljević V
    Med Pregl; 2002; 55(11-12):506-12. PubMed ID: 12712895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic resistance of microorganisms involved in ear, nose and throat infections.
    Baquero F; Loza E
    Pediatr Infect Dis J; 1994 Jan; 13(1 Suppl 1):S9-14; discussion S20-2. PubMed ID: 8159522
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical and pharmacokinetic studies on enoxacin in ear, nose and throat infections.
    Federspil PJ; Lind A; Tiesler E; Schmidt B
    Infection; 1986; 14 Suppl 3():S211-2. PubMed ID: 3463545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A meaningful antibiotic therapy of diseases of the ear, nose and throat in old age (author's transl)].
    Glaninger J
    Aktuelle Gerontol; 1978 Sep; 8(9):493-502. PubMed ID: 30329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations about the relationship of inhibitory concentrations and the pharmacologic and toxic properties of antimicrobial agents.
    Neu HC
    Diagn Microbiol Infect Dis; 1983 Mar; 1(1):41-7. PubMed ID: 6671364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of ofloxacin in otorhinolaryngologic infections].
    Forno-Pizzoglio M; Cuffini AM; Carlone NA; Cavallo GP
    G Batteriol Virol Immunol; 1986; 79(1-6):154-60. PubMed ID: 3479369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current mechanisms of resistance to antimicrobial agents in microorganisms causing infection in the patient at risk for infection.
    Neu HC
    Am J Med; 1984 May; 76(5A):11-27. PubMed ID: 6372459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pharmacokinetic studies of sulbactam/penicillin combinations in the treatment of ear, nose and throat infections.
    Federspil P; Schedler M; Kurt P; Tiesler E
    Drugs; 1988; 35 Suppl 7():80-3. PubMed ID: 3220011
    [No Abstract]   [Full Text] [Related]  

  • 11. [Guidelines for fighting penicillin resistant agents in the ear-nose-throat area].
    Schaal KP
    HNO; 1970 Apr; 18(4):105-11. PubMed ID: 4987429
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of ear, nose and throat infections with clofoctol.
    Ghilardi PL; Casani A
    Drugs Exp Clin Res; 1985; 11(11):815-8. PubMed ID: 3915468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from patients in primary hospitals in Shanghai from 2007 to 2010].
    Zhou CM; Hu BJ; Gao XD; Bao R; Xie HM; Huang SL; Tao LL; He LX
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 May; 36(5):346-50. PubMed ID: 24047808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of the microbiome in otorhinolaryngology].
    Fekete S; Szabó D; Tamás L; Polony G
    Orv Hetil; 2019 Sep; 160(39):1533-1541. PubMed ID: 31544493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of penicillin and trimethoprim-sulfamethoxazole in the treatment of ear, nose and throat infections.
    Quick CA
    Can Med Assoc J; 1975 Jun; 112(13 Spec No):83-6. PubMed ID: 805651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The clinical study of azithromycin in otolaryngologic infection].
    Naoya M
    Jpn J Antibiot; 2000 Jun; 53 Suppl B():103-10. PubMed ID: 12572093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antibiotic therapy of infections involving throat, nose and ears].
    Federspil P; Bach R
    ZFA (Stuttgart); 1980 Dec; 56(34):2331-48. PubMed ID: 7467801
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients.
    Jones RN
    Am J Med; 1996 Jun; 100(6A):3S-12S. PubMed ID: 8678095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Estimation of level of aminoglycosides susceptibility of bacterial strains isolated from patients with systemic and general infections].
    Kowalska-Krochmal B; Dolna I; Dobosz A; Wrzyszcz E; Gościniak G
    Med Dosw Mikrobiol; 2008; 60(3):205-14. PubMed ID: 19143174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.